Biogen’s stock hit by soft guidance and a decline in sales of MS drugs

6 months ago 25
ARTICLE AD BOX
Sales of an Alzheimer’s disease treatment were better than expected, but that and a quarterly beat wasn’t enough to offset below-consensus EPS outlook.
Read Entire Article
  1. Homepage
  2. Finance
  3. Biogen’s stock hit by soft guidance and a decline in sales of MS drugs

Related

Nvidia’s upstart Chinese rival Cambricon just showed 4,000% growth — but don’t get too excited

Nvidia’s upstart Chinese rival Cambricon just showed 4,000% ...

21 minutes ago 0
Trump’s Fed attack adds to fear Treasurys, dollar face emerging market-style risks

Trump’s Fed attack adds to fear Treasurys, dollar face emerg...

1 hour ago 0
A $400 billion bonanza? As AI spending estimates move higher, so do the stakes for investors.

A $400 billion bonanza? As AI spending estimates move higher...

1 hour ago 0

Trending

1. sean clifford
2. javon baker
3. benfica - fenerbahçe
4. celta de vigo - betis
5. champions league
6. oxford utd vs brighton
7. grimsby town vs man united
8. everton vs mansfield town
9. fulham vs bristol city
10. wehen wiesbaden - bayern

Popular

Netflix scuttles plans to add six previously announced games to its service

Netflix scuttles plans to add six previously announced games...

6 months ago 273
Can Pidcock win big & why did it end at Ineos?

Can Pidcock win big & why did it end at Ineos?

5 months ago 248
Steam will label early access games that haven't been updated in a year

Steam will label early access games that haven't been update...

6 months ago 232
OpenAI co-founder John Schulman has left Anthropic after less than a year

OpenAI co-founder John Schulman has left Anthropic after les...

6 months ago 231
Google's Magic Editor will watermark its AI-tweaked photos

Google's Magic Editor will watermark its AI-tweaked photos

6 months ago 221
English (US) English (US) ·
About Us · Contact Us · Terms & Conditions ·

© Nexa News 2025. All rights are reserved